Literature DB >> 2872526

Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population.

T Hovi, K Cantell, A Huovilainen, E Kinnunen, T Kuronen, K Lapinleimu, T Pöyry, M Roivainen, N Salama, M Stenvik.   

Abstract

An outbreak of 9 cases of paralytic poliomyelitis and 1 non-paralytic case occurred in Finland between August, 1984, and January, 1985, after two decades of freedom from the disease attributable to a successful immunisation programme. During the outbreak poliovirus type 3 was isolated from the patients, from about 15% of healthy persons tested, and from sewage water. At least 100 000 persons were estimated to have been infected. With 1.5 million extra doses of inactivated poliovirus vaccine to children under 18 years of age and an oral poliovirus vaccine campaign covering about 95% of the entire population in February-March, 1985, the outbreak was halted in February, 1985. Impaired herd immunity to the epidemic strain of poliovirus type 3, which differed from the type 3 vaccine strains in both immunological and molecular properties, was important in the emergence of this outbreak. The inactivated poliovaccine that had been used in the vaccination programme was relatively weakly immunogenic, especially as regards the type 3 component. Whether continuous antigenic variation of poliovirus type 3 has wider epidemiological implications is not known.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872526     DOI: 10.1016/s0140-6736(86)91566-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

1.  Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority.

Authors:  Y Manor; R Handsher; T Halmut; M Neuman; A Bobrov; H Rudich; A Vonsover; L Shulman; O Kew; E Mendelson
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

2.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  The clinical task.

Authors:  J Sheppard
Journal:  BMJ       Date:  1992-08-01

4.  Could an outbreak of poliomyelitis occur in the UK?

Authors:  D Brown; N Begg; B Wiratunga
Journal:  BMJ       Date:  1992-03-07

Review 5.  Poliomyelitis: eradication in sight.

Authors:  J L Melnick
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

Review 6.  Primary prevention and international travel: infections, immunizations, and antimicrobial prophylaxis.

Authors:  G S Ferenchick; D H Havlichek
Journal:  J Gen Intern Med       Date:  1989 May-Jun       Impact factor: 5.128

7.  Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.

Authors:  M Roivainen; T Hovi
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

8.  A ten-year experience in control of poliomyelitis through a combination of live and killed vaccines in two developing areas.

Authors:  T Tulchinsky; Y Abed; S Shaheen; N Toubassi; Y Sever; M Schoenbaum; R Handsher
Journal:  Am J Public Health       Date:  1989-12       Impact factor: 9.308

9.  An Environmental Surveillance in Uruguay Reveals the Presence of Highly Divergent Types of Human Enterovirus Species C and a High Frequency of Species A and B Types.

Authors:  Andrés Lizasoain; Fernanda M Burlandy; Matías Victoria; Luis F López Tort; Edson E da Silva; Rodney Colina
Journal:  Food Environ Virol       Date:  2018-06-16       Impact factor: 2.778

10.  Proportions of immunoglobulin isotypes in paralytic poliomyelitis and after vaccination.

Authors:  I Julkunen; P Ukkonen; M Stenvik; T Hovi; L Renkonen; O Mäkelä
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.